Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Oncozyme Pharma
Montreal, Quebec, Canada
- Ownership
- Private
- Development stage
- Other
01
Overview
OncoZyme Pharma was a Canadian biotechnology company focused on the development of innovative small molecule therapies for the treatment of cancer. The company's primary research centered on matrix metalloproteinase (MMP) inhibitors, which are designed to prevent the degradation of the extracellular matrix and inhibit tumor growth and metastasis. Its lead clinical candidate, OZP-002, was developed to target specific MMPs involved in cancer progression while minimizing the side effects typically associated with broad-spectrum MMP inhibitors. Although the company reached early clinical stages, it is no longer active in the biotechnology sector.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Oncozyme Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oncozyme Pharma.